Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

3 results about "Chromaffin cell" patented technology

Chromaffin cells, also pheochromocytes, are neuroendocrine cells found mostly in the medulla of the adrenal glands in mammals. These cells serve a variety of functions such as serving as a response to stress, monitoring carbon dioxide and oxygen concentrations in the body, maintenance of respiration and the regulation of blood pressure. They are in close proximity to pre-synaptic sympathetic ganglia of the sympathetic nervous system, with which they communicate, and structurally they are similar to post-synaptic sympathetic neurons. In order to activate chromaffin cells, the splanchnic nerve of the sympathetic nervous system releases acetylcholine, which then binds to nicotinic acetylcholine receptors on the adrenal medulla. This causes the release of catecholamines. The chromaffin cells release catecholamines: ~80% of adrenaline (epinephrine) and ~20% of noradrenaline (norepinephrine) into systemic circulation for systemic effects on multiple organs (similarly to secretory neurones of the hypothalamus), and can also send paracrine signals. Hence they are called neuroendocrine cells.

New use of bifidobacterium breve ccfm1078 for the relief of colic

This invention discloses a novel application of Bifidobacterium breve CCFM1078 in relieving intestinal colic, belonging to the fields of microbial technology and pharmaceutical technology. The Bifidobacterium breve CCFM1078 provided by this invention can relieve intestinal colic in infants and young children, specifically in the following ways: (1) increasing the visceral pain threshold and reducing the frequency of defecation in rats to a certain extent; (2) reducing the number of chromaffin cells and 5-HT content in the colon of rats with intestinal colic; (3) reducing the serum TNF-α and IL-1β content in rats with intestinal colic; (4) reducing the hippocampal TNF-α and IL-6 content in rats with intestinal colic; and (5) increasing the propionic acid content in the cecal contents of rats with intestinal colic.
Owner:WUXI INSTITUTE FOR SPECIALIZED NUTRITION & HEALTH CO LTD

Bifidobacterium longum subsp. infantis ccfm1269 for the relief of intestinal colic

PendingCN122321008APropanoic acidVisceral pain
This invention discloses the application of Bifidobacterium longum infantis subspecies CCFM1269 in relieving colic, belonging to the fields of microbial technology and pharmaceutical technology. The Bifidobacterium longum infantis subspecies CCFM1269 provided by this invention can relieve colic in infants and young children, specifically in the following ways: (1) increasing the visceral pain threshold in rats and reducing the visceral sensitivity of rats with colic; (2) reducing the number of chromaffin cells and 5-HT content in the colon of rats with colic; (3) reducing the serum TNF-a content in rats with colic; (4) reducing the hippocampal TNF-a and IL-6 content in rats with colic; and (5) increasing the content of butyric acid and propionic acid in the cecal contents of rats with colic.
Owner:WUXI INSTITUTE FOR SPECIALIZED NUTRITION & HEALTH CO LTD

Biomarkers for diagnosis and treatment of endocrine hypertension, and methods of identification thereof

PendingUS20260148848A1Medical data miningDrug and medicationsPheochromocytomaMetabolite
The disclosure relates to a combination of biomarkers comprising at least: (i-a) one biomarker selected in each of the following group of biomarkers: Patient's age, Plasma steroids, and Urinary steroids, and at least one biomarker selected in at least one of the group of biomarkers: O-methylated catecholamines, Small metabolites, and miRNA; or (i-b) one biomarker selected in each of the following group of biomarkers: Plasma steroids, Urinary steroids, and Small metabolites, and at least one biomarker selected in at least one of the group of biomarkers: Patient's age, O-methylated catecholamines, and miRNA. The combinations of biomarkers may be used for stratifying a hypertensive patient among different hypertensive diseases comprising Endocrine Hypertension (EHT), Primary Aldosteronism (PA), Pheochromocytoma / Functional Paraganglioma (PPGL), Cushing's Syndrome (CS), and Primary Hypertension (PHT).
Owner:INST NAT DE LA SANTE & DE LA RECHERCHE MEDICALE (INSERM) +7